August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.
The QIAseq xHYB CGP portfolio is being expanded to offer DNA and RNA panels to capture critical genomic regions, designed to leverage actionable and interpretable variants sourced from the Human Somatic Mutation Database from QDI. The QIAcuity RCL quant kit and QIAcuity CGT dPCR assays support quality control in cell and gene therapy with solutions for lentivirus-based applications.
The company is building its existing partnership with Element Biosciences by adding the QIAseq xHYB CGP panels to Element’s Aviti platform and Trinity workflow. In its partnership with Myriad Genetics, Qiagen said it plans to launch worldwide, with the exclusion of Japan, a sequencing-based homologous recombination deficiency assay designed to enable deeper molecular insights into DNA repair deficiencies. In addition, Qiagen is introducing HSMD Research, a free, limited version of its HSMD database to make genomic data more widely available.
Qiagen, 240-686-7700